Corrigendum

In the Research Article by Keith A Betts, Per-Olof Thuresson, Federico Felizzi, Ella X Du, Ibou Dieye, Jia Li, Mathias Schulz & Anthony S Masaquel: ‘US cost–effectiveness of polatuzumab vedotin, bendamustine and rituximab in diffuse large B-cell lymphoma’, which appeared in the October 2020 issue of the Journal of Comparative Effectiveness Research (9[14], 1003–1015 [2020]; https://www.futuremedicine.com/doi/10.2217/cer-2020-0057), Figure 5 appeared incorrectly. Figure 5 is correctly presented above.

The editors would like to sincerely apologize for any inconvenience or confusion this may have caused.